{
    "2019-07-21": [
        [
            {
                "time": "2019-07-21",
                "original_text": "【西南医药|0721周报】科创板正式落地，重点推荐南微医学+心脉医疗",
                "features": {
                    "keywords": [
                        "科创板",
                        "南微医学",
                        "心脉医疗"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-07-20",
                "original_text": "【国盛医药张金洋团队】周观点：详解2019Q2机构医药持仓，继续推荐2+X主线",
                "features": {
                    "keywords": [
                        "2019Q2",
                        "机构持仓",
                        "医药",
                        "2+X主线"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-20",
                "original_text": "【申万零售】南京新百（600682）：丹瑞项目定增完成，打造更加广阔的细胞治疗平台",
                "features": {
                    "keywords": [
                        "南京新百",
                        "丹瑞项目",
                        "定增完成",
                        "细胞治疗平台"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-07-20",
                "original_text": "【东吴医药】周观点20190720：关注科创板南微医学和心脉医疗",
                "features": {
                    "keywords": [
                        "科创板",
                        "南微医学",
                        "心脉医疗"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}